• Development of translational research studies (both animal and clinical) in cerebrovascular diseases, aiming to increase knowledge of the pathogenesis of cerebral infarction and cerebral haemorrhage. Analysing the influence of hyperglycaemia on stroke progression. Identifying prognostic biomarkers and therapeutic targets primarily aimed at brain protection and repair (cell therapy, trophic factors, extracellular vesicles). Analysing the contribution of comorbidities to the mechanisms occurring after stroke in animal models.
• Clinical trials on cell therapy in acute cerebral infarction (AMASCIS clinical trial).
• Study of the clinical (neurological and neuropsychological) and anthropological factors influencing functional recovery and reintegration of stroke patients, as well as adherence to recommendations for secondary stroke prevention.
• Analysing post-stroke aphasia recovery through a dubbing tool and the development of a communication app (VerbalizApp).
• Evaluating the use of virtual reality in the recovery of motor and cognitive sequelae post-stroke, as well as computational movement analysis.
• Assessing the efficacy of maintaining oral or parenteral anticoagulation in the acute phase of cardioembolic ischaemic stroke.
• Identifying factors predicting the development of atrial fibrillation through abnormalities in electrocardiograms and echocardiograms in cryptogenic stroke.
• Analysis of patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) in stroke.
• Comparing general anaesthesia and high-flow nasal cannula sedation in endovascular treatment of ischaemic stroke.
 

• Analysis of the expression of central pain awareness in different primary and secondary headaches.
• Central sensitisation and pain perception in patients with cluster headache.
• Refractory migraine database.
• Short-term prophylaxis of cluster headache: A comparative study.
• Study of chronic craniofacial neuropathic pain.
• CGRP pathway drugs in patients with refractory migraine (including autoimmune diseases and elderly patients) and medication-overuse headache.
• Multicentre collaboration in post-COVID headache research.
• Characteristics and outcomes of chronic refractory cluster headache treated with occipital nerve stimulation.
• Chronic cluster headache registry.
• Treatment of chronic cluster headaches with transcranial magnetic stimulation. Clinical study.
 

• Study of the involvement of the lysosomal pathway in a model of neurodegeneration and cholesterol dysregulation in Alzheimer’s disease.
• Study of genetic polymorphisms related to PSP within a multicentre genome-wide association study (GWAS).
 

• Tremor as a negative predictive factor in the development of dementia associated with Parkinson’s disease.
• Assessment of the benefits and risks of continuous intraduodenal levodopa infusion in idiopathic Parkinson’s disease.
 

• Assessment of therapeutic response to enhanced Frenkel training exercises using the Wii console in patients with cerebellar ataxia.
• Participation in the European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS) registry, aimed at improving knowledge of epigenetic mechanisms related to frataxin expression silencing and disease pathogenesis, identifying biomarkers and modifier genes of clinical expression, developing new therapies, and creating cellular and animal models for studying Friedreich’s ataxia.